Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-18
2011-11-01
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S241000, C514S256000, C514S291000, C514S292000, C514S293000, C546S081000, C546S082000, C546S084000, C546S139000, C546S152000, C540S577000
Reexamination Certificate
active
08048895
ABSTRACT:
Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.
REFERENCES:
patent: 5128118 (1992-07-01), Carroll et al.
patent: 5141959 (1992-08-01), Carroll et al.
patent: 5298499 (1994-03-01), Carroll et al.
patent: 5380848 (1995-01-01), Kuhar et al.
patent: 5411965 (1995-05-01), Reid et al.
patent: 5413779 (1995-05-01), Kuhar et al.
patent: 5496953 (1996-03-01), Kuhar et al.
patent: 5736123 (1998-04-01), Carroll
patent: 5831095 (1998-11-01), Gonzalez et al.
patent: 5935953 (1999-08-01), Kuhar et al.
patent: 6123917 (2000-09-01), Carroll
patent: 6329520 (2001-12-01), Carroll et al.
patent: 6358492 (2002-03-01), Kuhar et al.
patent: 6416735 (2002-07-01), Carroll et al.
patent: 6479509 (2002-11-01), Carroll
patent: 6531481 (2003-03-01), Carroll et al.
patent: 6531483 (2003-03-01), Kuhar et al.
patent: 6538010 (2003-03-01), Carroll
patent: 6552032 (2003-04-01), Carroll et al.
patent: 6559159 (2003-05-01), Carroll et al.
patent: 6593348 (2003-07-01), Carroll et al.
patent: 6706880 (2004-03-01), Carroll et al.
patent: 6900228 (2005-05-01), Carroll et al.
patent: 6974824 (2005-12-01), Carroll et al.
patent: 7011813 (2006-03-01), Kuhar et al.
patent: 7189737 (2007-03-01), Kuhar et al.
patent: 7291737 (2007-11-01), Kuhar et al.
patent: 2002/0132828 (2002-09-01), Carroll et al.
patent: 2003/0158415 (2003-08-01), Carroll et al.
patent: 2003/0176434 (2003-09-01), Carroll
patent: 2004/0146518 (2004-07-01), Carroll et al.
patent: 2006/0069111 (2006-03-01), Carroll
patent: 2006/0183743 (2006-08-01), Frank et al.
patent: 2006/0241135 (2006-10-01), Carroll et al.
patent: 2007/0027182 (2007-02-01), Carroll et al.
patent: 2009/0264462 (2009-10-01), Carroll et al.
patent: WO 02/053533 (2002-07-01), None
U.S. Appl. No. 12/551,072, filed Aug. 31, 2009, Carroll.
P. Portoghese, “The Design of δ-Selective Opioid Receptor Antagonists”, IL Fannaco, 1993, vol. 48, No. 2, pp. 243-251.
P. Portoghese et al., “Binaltorphimine and Nor-Binaltorphimine, Potent and Selective κ-Opioid Receptor Antagonists”, Life Sciences., 1987, vol. 40, No. 13, pp. 1287-1292.
S. Olmsted, et al., “A Remarkable Change of Opioid Receptor Selectivity on the Attachment of a Peptidomimetic κ Address Element to the δ Antagonist, Natrindole: 5′-[ (N2-Alkylamidino)methyl]naltrindole Derivatives as a Novel Class of κ Opioid Receptor Antagonists”, J. Med. Chem., 1993, vol. 36, No. 1, pp. 179-180.
R. Jones, et al., “Mutational Evidence for a Common κ Antagonist Binding Pocket in the Wild-Type κ and Mutant μ[K303E] Opioid Receptors†”, The Journal of Medical Chemistry, vol. 41, No. 25, Dec. 3, 1998, pp. 4911-4914.
R. Schwyzer, “ACTH: A Short Introductory Review”, Ann. N. Y. Acad. Sci., 1977, vol. 247, pp. 3-26.
K. Trujillo, et al., Changes in Prodynorphin Peptide Content Following Treatment with Morphine or Amphetamine: Possible Role in Mechanisms of Action of Drug of Abuse:, NIDA Res. Monogr., 1989, vol. 95, pp. 550-551.
P. Smiley, et al., “Effects of Cocaine on Extrapyramidal and Limbic dynorphin systems1”, J. Pharmacol. Exp. Ther.,vol. 253, No. 3, 1990, pp. 938-943.
A. Corbett, et al., “Dynorphin1-8and Dynorphin1-9are Ligands for the κ-Subtype of Opiate Receptor”, Nature, vol. 299, No. 5878, 1982, pp. 79-81.
R. Spangle, et al., “Opposing Tonically Active Endogenous Opioid Systems Modulate the Mesolimbic Dopaminergic Pathway”, Proc. Natl. Acad. Sci. USA, vol. 89, 1992, pp. 2046-2050.
R. Spangle, et al., “Modulation of Morphine-Induced Sensitization by Endogenous κ-Opioid systems in the rat”, Neurosci. Lett., vol. 153, 1993, pp. 232-236.
J. Zadina et al., “A Potent and Selective Endogenous Agonist for The μOpiate Receptor”, Nature, vol. 386, 1997, pp. 499-502.
D. Zimmerman, et al., “New Structural Concepts for Narcotic Antagonists Defined in A 4-Phenylpiperidine Series”, Nature, vol. 275, 1978, pp. 332-334.
D. Zimmerman, et al., “Further Investigation of Novel 3-methyl-4-phenylpiperidine Narcotic Antagonists”, In Proceedings of the 40thAnnual Scientific Meeting of the Committee on Problems of Drug Dependence, 1978, pp. 237-247.
D. Zimmerman, et al., “Structural Requirements for Affinity and Intrinsic Activity At The Opiate Receptor Defined in 4-Phenylpiperidine and Related Series”, In Problems of Drug Dependence, 1981, Proceedings of the 43rdAnnual Scientific Meeting, The committee on Problems of Drug-Dependence, Inc., NIDA Research Monograph., vol. 41, 1982, pp. 112-118.
D. Zimmerman, et al., “Synthesis and Analgesic Properties of N-Substituted trans-4a-Aryldecahydroisoquinolines”, J. Med. Chem., vol. 31, 1988, pp. 555-560.
D. Zimmerman, et al., “Structure-Activity Relationships of trans-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine Antagonists for μ- and κ-Opioid Receptors”, J. Med. Chem., vol. 36, No. 20, 1993, pp. 2833-2841.
D. Zimmerman, et al., “Opioid Receptor Antagonists: Comparison of trans-3-,4-dimethyl-4-phenylpiperidines and Their Use In The Development of A Model Of Opioid Receptors”, Pharmacol. Rev. in Press.
U.S. Appl. No. 08/506,541, file Jul. 24, 1995, Kuhar, et al.
U.S. Appl. No. 08/701,503, file Aug. 22, 1996, Carroll, et al.
U.S. Appl. No. 60/107,902, file Nov. 10, 1998, Carroll, et al.
U.S. Appl. No. 09/537,668, file Mar. 29, 2000, Carroll, et al.
U.S. Appl. No. 10/259,780, filed Sep. 30, 2002, Carroll, et al.
U.S. Appl. No. 11/863,587, file Sep. 28, 2007, Kuhar, et al.
U.S. Appl. No. 12/911,244, filed Oct. 25, 2010, Carroll, et al.
J. Aldrich, “Analgesics”, In Burger's Medicinal Chemistry and Drug Discovery, Wolff, M.E. Eds.; John Wiley & sons: New York, 1996, vol. 3.
J. Volpicelli, et al., “Naltrexone in the Treatment of Alcohol Dependence”, Arch. Gen. Psychiatry, 1992, vol. 49, pp. 876-880.
J. Volpicelli, et al. “Effect of Naltrexone on Alcohol “high” in Alcoholics”, Am. J. Psychiatry, 1995, vol. 152, pp. 613-615.
A. Marki, et al., “μ-Opioid Receptor Specific Antagonist Cyprodime: Characterization by In Vitro Radioligand and [35S]GTPγS Binding Assays”, Eur. J. Pharmacol, 1999, vol. 383, No. 2, pp. 209-214.
J. Thomas, et al., “Investigation of the N-Substituent Conformation Governing Potency and μ Receptor Subtype-Selectivity in (+)-(3R,4R)-Dimethyl-4-(3-hydroxyphenyl)-piperidine Opioid Antagonists”, J. Med. Chem., vol. 41, No. 11, 1998, pp. 1980-1990.
J. Thomas, et al., “Identification of an Opioid K Receptor Subtype-Selective N-Substituent for (+)-(3R,4R)-Dimethyl-4-(3-hydroxyphenyl)piperidine”, J. Med. Chem., vol. 41, No. 26, 1998, pp. 5188-5197.
J. Werner, et al., “Synthesis oftrans-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine Opioid Antagonists: Application of theCis-Thermal Elimination of Carbonates to Alkaloid Synthesis”, J. Org. Chem., vol. 61, 1996, pp. 587-597.
Cai Tingwei
Carroll Frank Ivy
Navarro Hernan A.
Thomas James B.
Javanmard Sahar
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Padmanabhan Sreeni
Research Triangle Institute
LandOfFree
Kappa opioid receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kappa opioid receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kappa opioid receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4259699